FAMTX versus etoposide, doxorubicin, and cisplatin: A random assignment trial in gastric cancer Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Stomach Neoplasms

abstract

  • FAMTX is at least as active as EAP and is significantly less toxic. Although both regimens remain investigational, the toxicities of FAMTX are more manageable. Further studies involving FAMTX in both the adjuvant and advanced disease setting are underway.

publication date

  • December 1992

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed ID

  • 1548519

Additional Document Info

start page

  • 541

end page

  • 8

volume

  • 10

number

  • 4